Franklin Chiu-Leung Wong, M.D., Ph.D., J.D., M.B.A.

Peer-Reviewed Articles

1. Eldaya RW, Calle S, Wong FCL, Learned KO, Wintermark M. Parathyroid carcinoma: Imaging features of initial presentation and recurrence. A single center experience. Neuroradiol J 37(1):19714009231212361, 2024. e-Pub 2023. PMID: 37934201.
2. Surasi DSS, Lin L, Ravizzini G, Wong F. Supraclavicular and Axillary Lymphadenopathy Induced by COVID-19 Vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT. Clin Nucl Med. e-Pub 2021. PMID: 34507331.
3. Wong FC, Martiniova L, Masrani A, Ravizzini GC. 18F-Fluciclovine-Avid Reactive Axillary Lymph Nodes After COVID-19 Vaccination. Clin Nucl Med. e-Pub 2021. PMID: 34183501.
4. Coroneos CJ, Woodward WA, Wong FC, Caudle AS, Shaitelman SF, Kuerer HM, Schaverien MV. Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer. J Surg Oncol 123(4):846-853, 2021. e-Pub 2020. PMID: 33333583.
5. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Complete Metabolic Response on Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Oncologist 22(5):526-534, 2017. e-Pub 2017. PMID: 28377466.
6. Nguyen AT, Suami H, Hanasono MM, Womack VA, Wong FC, Chang EI. Long-term outcomes of the minimally invasive free vascularized omental lymphatic flap for the treatment of lymphedema. J Surg Oncol 115(1):84-89, 2017. e-Pub 2016. PMID: 27439587.
7. Wong FC. Brain Tumor Imaging. J Nucl Med. e-Pub 2016. PMID: 27856626.
8. Logan JK, Park PC, Wong FC, Erwin WD, Beddar S, Kaseb AO, Crane CH, Koay EJ. Outcomes of Patients With Hepatocellular Carcinoma and Advanced Cirrhosis After High-Dose Radiation Therapy Guided by Functional Liver Imaging With Tc99m Sulfur Colloid Liver SPECT-CT. Int J Radiat Oncol Biol Phys 96(2S):E167-E168, 2016. PMID: 27673954.
9. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer 121(22):3965-74, 2015. e-Pub 2015. PMID: 26249241.
10. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2014. PMID: 25155428.
11. Wong FC, Boja J, Ho B, Kuhar MJ, Wong DF. Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations. Biomed Res Int 2013:Article ID 503095, 2013. e-Pub 2013. PMID: 23936811.
12. Hulme KW, Rong J, Chasen B, Chuang HH, Cody DD, Wong FC, Kappadath SC. A CT acquisition technique to generate images at various dose levels for prospective dose reduction studies. AJR Am J Roentgenol 196(2):W144-51, 2011. PMID: 21257855.
13. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A Phase 2 Study of Yttrium-90 Ibritumomab Tiuxetan (Zevalin) in Patients With Chronic Lymphocytic Leukemia. Cancer 115(19):4533-4539, 2009. PMID: 19637351.
14. Wong FC, Kim EE. Molecular Imaging: Translation from Rats to Dogs and Humans. CMIR 5(3):137-143, 2009.
15. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 27(20):3319-24, 2009. e-Pub 2009. PMID: 19414670.
16. Younes A, Wong F. Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology 20(6):1147-8, 2009. e-Pub 2009. PMID: 19465429.
17. Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 70(2):205-211, 2009. e-Pub 2009. PMID: 19299097.
18. Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 22(4):237-43, 2008. e-Pub 2008. PMID: 18535873.
19. Kim EE, Yang DJ, Wong FC. FDG-PET/CT and SPECT/CT in Oncology. Current Medical Imaging 4(1):63-9, 2008.
20. Spiess PE, Izawa JI, Bassett R, Kedar D, Busby JE, Wong F, Eddings T, Tamboli P, Pettaway CA.. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urology 177(6):2157-2161, 2007. PMID: 17509308.
21. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy. J Clin Oncol 23(31):7904-7910, 2005. PMID: 16258090.
22. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective p-glycoprotein (P-gp) inhibitor, in chemotherapy-resistant advanced breast cancer. Cancer 104(4):682-91, 2005. PMID: 15986399.
23. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bhara S, McMurray JS, Lang FF, Wong FC, Sawaya R, Yung Wk, Fueyo J.. Delta24-hyDC adenovirus suppresses glioma growth in vivo by combining oncolysis and chemo sensitization. Cancer Gene Ther 12(3):284-294, 2005. PMID: 15650766.
24. Izawa J, Kedar D, Wong F, Pettaway CA. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol 12 Suppl 1:24-9, 2005. PMID: 15780161.
25. Hentschel SJ, Rhines LD, Wong FC, Gokaslan ZL, McCutcheon IE. Subarachnoid-pleural fistula after resection of thoracic tumors. J Neurosurg 100(4 Suppl Spine):332-336, 2004. PMID: 15070140.
26. Wong FC, Swartz BE, Gee M, Mandelkern M. Occipital hypometabolism demonstrated by positron emission tomography after temporal lobectomy for refractory epilepsy. J Neuroophthalmol 24(1):19-23, 2004. PMID: 15206433.
27. Sparks RB, Crowe EA, Wong FC, Toohey RE, Siegel JA. Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: The potential for toxicity. J Nucl Med 43:1110-1114, 2002. PMID: 12163638.
28. Oriuchi N, Korkmaz M, Kim EE, Delpassand ES, Wong FC, Wallace S, Podoloff DA. Role of indium-111 labeled platelet scintigraphy in the management of thrombocytopenic patients with malignant neoplasms. Eur J Nucl Med 25(3):247-252, 1998.
29. Milas M, Feig B, Yu D, Oriuchi N, Cromeens D, Ge T, Wong FC, Kim EE, Pollock R. Isolated limb perfusion in the sarcoma-bearing rat: A novel preclinical gene delivery system. Clin Cancer Res 3:2197-2203, 1997. PMID: 9815615.
30. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Buzdar AU, Podoloff DA. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging 21(5):332-336, 1997. PMID: 9316752.
31. Kim C-G, Kim EE, Kim HJ, Choe JG, Hong SC, Wong FC, Theriault RL, Nicolson GL, Podoloff DA. Correlation between bone scan findings and collagenase activities in patients with breast cancer. Invest Radiol 32(5):302-305, 1997. PMID: 9140751.
32. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, Podoloff DA. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 37((9):1476-1479, 1996. PMID: 8790197.
33. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Korkmaz M, Tansey W, Hicks K, Podoloff DA. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 37(9):1472-1476, 1996. PMID: 8790196.
34. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study. Cancer Biother Radiopharm 11(4):235-245, 1996. PMID: 10851543.
35. Korkmaz M, Kim EE, Wong FC, Podoloff DA. Vascular metastatic lesion in the pelvis mimicking gastrointestinal bleeding. Clin Nucl Med 21:644-645, 1996. PMID: 8853920.
36. Korkmaz M, Kim EE, Wong FC, Podoloff DA. C-11 methionine and F-18 FDG uptake in a patient with meningioma and glioblastoma multiforme. Clin Nucl Med 21(7):580-582, 1996. PMID: 8818480.
37. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37(6):931-938, 1996. PMID: 8683314.
38. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13(11):2827-2834, 1995. PMID: 7595745.
39. Austin JR, Wong FC, Kim EE. Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 113(4):404-407, 1995. PMID: 7567012.
40. Korkmaz M, Kim EE, Wong FC, Podoloff DA, Haynie TP, Yang DJ. In-111 DTPA Ommayagram in leptomeningeal carcinomatosis. Clin Nucl Med 20:610-612, 1995. PMID: 7554663.
41. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36(5):788-793, 1995. PMID: 7738649.
42. Meyers CA, Valentine AD, Wong FC, Leeds NE. Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: Correlation of SPECT with neuropsychological testing. J Neuropsychiatry and Clin Neurosci 6:285-288, 1994. PMID: 7950353.
43. Kim EE, Wong FCL, Wong WH, Tilbury R, Podoloff DA, Haynie, TP, Leeds NE, Yung AYK, Sawaya, R. PET in clinical neuro-oncology. Neuroimaging Clinics of North America 3 (4):771-778, 1993.
44. Halfman CJ, Wong FC, Jay DW. Solvent perturbation fluorescence immunoassay technique. Anal Chem 57(9):1928-31, 1985. PMID: 3898914.
45. Halfman CJ, Wong FC, Schneider AS.. Directly measured signal as response variables in fluorescence polarization ligand binding assays. Anal Chem 56:1648-50, 1984. PMID: 6486446.
46. Wong FCL, Halfman CJ, Schneider AS. Optimization of competitive ligand binding assay by quantitative considerations. J Clin. Immunoassay 7(1):62, 1984.
47. Yew DT, Wong FCL, Chan YW.. Changes in laser-irradiated retina in the first 24h after irradiation. Acta. Anat 103:301-304, 1979.

Invited Articles

1. Kim EE, Lamki L, Podoloff DA, Wong FCL. Nuclear Medicine. Radiology 190(2):616-617, 1994. PMID: 7824749.

Abstracts

1. Wong FC. Functional liver volume from Tc99m sulfur colloid liver SPECT/CT correlates with outcomes of image-guided radiotherapy of liver in patients with cirrhosis. SNMMI 2016 Annual Meeting San Diego, CA, 2016.
2. Wong Wai-Hoi, Chen SuYun, Zheng Qian, Chen Mu, Bao Jun, Lv Zhongwei, Xu Baixuan, Shi, Hongcheng, Wong Franklin. A retrospective study to survey the detection of small lesions in state-of-the-art clinical PET/CT. J Nucl Med(56):1784, 2015.
3. Chen Suyun, Ibrahim, Nuhad K, Wong Stephen, Wang, Hui, Wong Franklin. Prognostic value of metabolic complete response on 18F-FDG PET/CT in stage II or III breast cancer patients treated with neoadjuvant chemotherapy. J Nucl Med(56):288, 2015.
4. Chen Suyun, Ibrahim Nuhad K, Wong Stephen, Wang Hui, Wong Franklin. Risk stratification in patients with newly diagnosed stage III or IV breast cancer by metabolic parameters of primary tumor in 18F-FDG PET/CT. J Nucl Med(56):1319, 2015.
5. Wong Franklin, Sparks Richard. Human radiation dosimetry models of F-18 FDG after intrathecal injection by intraventricular and intralumbar routes. J Nucl Med(56):1222, 2015.
6. Wong FCL, Vu TH, Wong ST, Schellingerhout D, Chuang HH, Guha-Thakurta N, Kim EE, Kappadath SC, Perrier N, Rohren EM. Localization of Parathyroid Adenomas by Tc99m Sestamibi SPECT-CT, Contrast-enhanced. RSNA 2013 Scientific Assembly and Annual Meeting, 2013.
7. Wong, FC, Sparks, RB. Radiation absorbed doses inside and outside of spheres up to 250ml for 22 radionuclides. J of Nuc Med 54(Supp 2):211P, 2013.
8. Wong FC, Naff K, Liu C, Ferguson A, Hwu P. Intratumoral positron emission cancer therapy (IPECT) using F-18 FDG, Cu-64 Cl and Ga-68 Cl. J of Nuc Med 54(Supp 2):313P, 2013.
9. Wong FC. Successful intratumoral radionuclide cancer therapy (IRCT) prevents growth of subsequently re-innoculated 13762 mammary tumors in rats. J of Nuc Med 53(Supp 1):54P, 2012.
10. Wong FCL. Comparison of ultrasonography, Tc-99m sestamibi SPECT-CT and contrast enhanced-CT in the localization of parathyroid adenoma. J of Nuc Med 52(Supp 1):166P, 2011.
11. Wong FC, McCutcheon IE, Groves M, and Kim EE. Evaluation of CSF Flow by whole-body scintigraphy. J of Nuc Med 51(Supp 2), 2010.
12. Kim EE, Song Y, Wong FC, Lee D, Perrier N. Correlation of 99mTc sestamibi uptake with size and weight of parathyroid adenoma as well as serum levels of calcium, PTH and vitamin D. J of Nuc Med 51(Supp 2), 2010.
13. Wong FC, Ahrar K, Wong A, Mawlawi O, Stafford J, Wong B, Tinkey P. Retention of Ga-68 Iron Macroaggregates (GIMA) after Intratumoral Injection in Canine Models. J of Nuc Med 50(Supp 2):337P, 2009.
14. Wong FC, Sparks RB. Radiation Dosimetry Models of Intraventricular Injection of 14 Radiopharmaceuticals. J of Nuc Med 50(Supp 2):393P, 2009.
15. Wong FC, Sparks RB. Radiation Dosimetry Models of Intralumbar Injection of 14 Radiopharmaceuticals. J of Nuc Med 50(Supp 2):393P, 2009.
16. Wong FC, Wong V, Sparks RB. Radiation Depth Dosimetry Models of 5-Spheres with Volumes between 0.4 and 250 ml. J of Nuc Med 50(Supp 2):394P, 2009.
17. Wong FC, Ahrar K, Wong AC, Mawlawi AC, Stafford J, Wong BS, Tinkey, P. A Canine cTVT Model for Metabolic Imaging of Tumors. World Molecular Imaging Congress, 2008.
18. Wong FC, Chickerneo F, Wong V, Wendt R. Simultaneous imaging of In-111 and Ga-67 and measurement of residence times after intramuscular injection in rats. J Nuc Med 49:102P, 2008.
19. Wong FC, Groves M, Conrad C, Puduvalli V, Meyers C, Kim S, Chickerneo F, Tummala S, Kim EE. A Phase I Study Using Intralumbar injection of I-131 Sodium Iodide To Treat Leptomeningeal Metastases (LM). Neurology 70(11 Supp 1):A160, 2008.
20. Wong FC, Chickerneo F, Wong V, Wendt R. Simultaneous imaging of In-111 and Ga-67 and measurement of residence times after intramuscular injection in rats. J Nuc Med 48(6):402P Sup 2, 2007.
21. Wendt RE, Erwin WD, Wong V, Wong FC. Separation of simultaneously acquired Ga-67 and In-111 images using principal component analysis. J Nuc Med 48(6):155P Supp 2, 2007.
22. Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Kim S, Puduvali V, Hsu S, Kim EE. Toxicity and efficacy profiles of intrathecal injection of I-131 Nal via intraventricular (IVent) or intralumbar (Ilumb) route for leptomeningeal metastases (LM) therapy. J Clin Oncol 24(No. 18 Part I of II):70s, 2006.
23. Namwongprom S, Wong FC, Kim EE, Boonyaprapa S. Correlation of chromogranin A (CgA) levels and somatostatin receptor scintigraphy (SRS) findings in the evaluation of cardioid tumors. J Nuc Med 47:166, 2006.
24. Wong FC, Groves M, Papadopulos N, Kim S, Conrad C, Meyers C, Fonnegra A, Puduvali V, Hsu S, Kim EE. A Phase I Study using I-131 Nal to Treat Leptomeningeal Metastis via Lumbar Puncture. J Nuc Med 47:80, 2006.
25. Wong FC, Groves M, Conrad C, Hsu S, Papadopulus N, Meyers C, Kim S, Fonnegra A, Podoloff DA, Kim EE. A Phase I Study of Intraventricular Injection of I-131 Sodium Iodide in Patients with Leptomeningeal Metastasis (LM). American Academy of Neurology Annual Meeting, 2006.
26. Wong FC, Wang S, Stachowiak A, Wang Y, Sparks RB. Human Radiation Dosimetry After Intraventricular Injection of I-131`Sodium Iodide. 52nd Annual Meeting of Society of Nuclear Medicine No. 1118, 2005.
27. Wong FC, Groves M, Hsu S, Conrad C, Kumar A, Fonnegra A, Wang Y, Pappadopoulus N, Sparks RB, Podoloff DA. Safety and Radiation Dosimetry Profiles of Intrathecal I-131 Sodium Iodide (Nal) in Patients with Leptomeningeal Metastasis (LM). J Clin Oncology, 2005 ASCO Annual Meeting Proceedings 23:16S, 2005.
28. Tu S, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin S, Logothetis CJ. Long-term effects of strontium-89 combined with chemotherapy in patients with androgen-independent prostate cancer and bone metastases. J Clin Oncology, 2005 ASCO Annual Meeting Proceedings 23:16S, 2005.
29. Wong FC, Wang S, Stachowiak AM, Wang Y, Sparks RB. Human dosimetry after Intraventricular Injection of I-131 Sodium Iodide. J Nuc Medicine 2005 Annual Meeting, 2005.
30. Wong FC, Fonnegra A, Wang Y.. Intratumoral Injection of I-131 Sodium Iodide suppresses Tumor Growth in a Rat Breast Cancer Model. Proc Amer Assoc Cancer Res 46:345, 2005.
31. Tu S-M, Wong FC. Strontium-89 combined with chemotherapy does not compromise subsequent therapy in selected patients with androgen-independent prostate cancer. J Clin Onc, 2005.
32. Wong FC, Wang Y, Fonnegra A, Kim EE. Sequestration of Particulate Radiopharmaceuticals after Intratumoral Injection into Breast Cancer Grafts in Rats. Era of Hope 2005, Department of Defense Breast Cancer Research No. 44, 2005.
33. Wong FC. Locgional Injection of F-18 Radiopharmaceuticals Suppresses Tumor Xenograft Growth in Rats. World J. of Nucl Med 3, 2004.
34. Kuang L, Sun W, Kim EE and Wong FC. F-18 FDG PET Is Better Than Bone Scan For The Detection Of Osseous Metastases In Patients With Treated Breast Cancer. J Nucl Med 45:153P, 2004.
35. Wong FC, Wang S. Paramagnetic Radiopharmaceuticals of Iron and Gadolinium Macroaggregates. Eur J Nucl Med Imaging 31(2 suppl):S387, 2004.
36. Wong FC, Wang S. Locoregional ablation of rat breast cancer using Ga-67 Iron macroaggregates (GIMA) and Y-90 Iron Macroaggregates (YIMA). Eur J Nucl Med. Imaging 31(2 Suppl):S297, 2004.
37. Wong FC. Locoregional Ablation of Rat Breast Cancer Using Y-90 Cl or In-111 Cl. J. Nucl. Med 45(5 suppl):334P, 2004.
38. Wong FC, Groves M, Sparks RB, Kim S, Hsu S, Conrad C, Pappadopoulus N, Podoloff DA, Sneige N, Meyers Cand Kim EE. A Phase I Study Of Beta-Emitter Ablative Therapy (BEAT) Using Intraventricular Injection Of I-131 NaI To Treat Leptomeningeal Metastasis. J Nucl Med 45(5 suppl):148P, 2004.
39. Wong FC, Smrkovski OA, Chow LY, Wang L, Sparks RB. Lower Radiation Dosimetric Estimates From Biodistribution Studies Of Parenteral Administration (IM OR IV) OF Y-90 Chloride. J Nucl Med 45:435P, 2004.
40. Wong FC and Sparks R B. Simulated Dosimetry Profiles of Locoregional Radionuclide Therapies using Radioactive Gallium Iron macroaggregates (GIMA). Euro J NaCl. Med. Imaging 3(2 Suppl):S293, 2004.
41. Wong FC, Wang, S, Podoloff DA, Kim EE. Kinetic modeling of physiologic human CSF flow and blockade. J Nucl Med 44(6), 2003.
42. Wong FC, Sparks R, Kim EE, Yang DJ, Podoloff DA. Simulation of radiation dosimetry in intra-cavitary injection of eight radionuclides in five shell models. J Nucl Med Forty-Ninth Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA 43:90, 2002.
43. Gayed I, Vu T, Macapinlac H, Delpassand E, Wong F, Kim E, Podoloff D. Comparison of bone and 18F FDG scans in the evaluation of bony metastases. J Nucl Med 43(5):285, 2002.
44. Sparks RB, Crowe EA, Wong FC, Toohey RE, Siegel JA. Radiation dose distributions in normal tissue due to adjacent tumors containing I-131 or 90Y: The potential for toxicity. J Nucl Med 43:91, 2002.
45. Wong FC, Sparks RB. Radiation dosimetry of radio-iodines (I-123, I-124, I-125 and I-131) from intraventricular injections into the human cerebral spinal fluid. Eur J Nucl Med 29(8):S172, 2002.
46. Wong FC, Sparks R. Radiation dosimetry of radioiodines I-123, I-124, I-125 and I-131 from intralumbar injection. J Nucl Med 43(5):87, 2002.
47. Wong FC, Sparks RB, Groves M, Kim EE, Conrad C, Wendt R, Stachowiak A, Erwin Wand Podoloff D. Preliminary results of phase I studies of intrathecal beta emitter ablative therapy of leptomeningeal metastasis using I-131 sodium iodide. Eur J Nucl Med 29(8):S172, 2002.
48. Wong FC, Kim E, Groves M, Conrad,C, McCutcheon I, Podoloff D. The clearance rates of In-111 DTPA from CSF vary with different sites of CSF blockade. Eur J Nucl Med 29(8):S286, 2002.
49. Shannon VR, Wong FC, Truong M, Davis J, Kim EE. Pulmonary embolism with thrombocytopenia and thrombocytosis. Chest 120(Supp 4), 2001.
50. Wong FC, Kim, EE, Sparks, R, Wong W-H, Yang DJ, Podoloff DA. Three Sphere Dosimetry Models (0.4 cc, 2cc and 10cc) of 12 Commonly Available Radionuclides for Locoregional Therapy or Extravasation. J Nucl Med 42(5):28, 2001.
51. Azhdarinia A, Yang DJ, Wong FC, Tansey LW, Inoue T, Kim EE and Podoloff, DA. Rapid synthesis of 18F-fluoropropyl-µ- methyltyrosine. J Nucl Med 41(5):243P, 2000.
52. Wong FC. ntratumoral Injection of I-131 Sodium Iodide Suppresses Tumor Growth in a Rat Breast Cancer Model. AACR, 2000.
53. Wong FC, Sparks R, Kim EE and Podoloff, DA. Simulated dosimetry of intraventricularly-injected beta emitters for ablative therapy against leptomeningeal metastasis in patients with or without CSF stasis. J Nucl Med 41(5):237P, 2000.
54. Wong FC, Swanston N, Kim, EE, Sherman, Sand Podoloff, DA. I-131 thyroid cancer scans under the stimulation of thyrogen (TTCS) identifies iodine-avid lesions less effectively than post-ablation thyroid cancer scan (PTCS). . J Nucl Med 41(5):274P, 2000.
55. Wong FC, Sparks, R, Kim, EE, Jaeckle, KA, Levin, VA, Pappadopoulos, NE, Podoloff, DA. Dosimetric Considerations for Intrathecal Beta-Emitters for Ablative Therapy (IBEAT) Against Leptomeningeal Metastasis (LM) Using Beta-emitting Radiopharmaceuticals. Neurology 54(7, Supp. 3):A37, 2000.
56. Wong FC, Swanston N, Kim EE, Nair N, Sherman S and Podoloff, DA. Post-Therapy I-131 scans (PRXS) identify more lesions in every patient than pre-therapy I-131 scans under thyrotropin alfa stimulation (TGS). . Clin Nucl Med 53(3):233, 2000.
57. Wong FC, Sparks R, Kim EE and Podoloff DA. Whole-body and depth dosimetry of intraventricular beta emitters for ablative therapy against leptomeningeal metastasis. Clin Nucl Med 53(3):233, 2000.
58. Wong FC, Kim EE, Jaeckle KA, McCutcheon I, Podoloff DA. CSF leakage is associated with shortened effective tracer half-life (TE) during a whole-body cisternogram. Eur J Nucl Med 27(8):1117, 2000.
59. Wong FC, Sparks R, Kim, EE, Wong W-H, Podoloff DA. Simulated dosimetry of intralumbar injection of beta-emitters for ablative therapy of leptomeningeal metastasis in patients with or without CSF stasis. Eur J Nucl Med 28((8)):924, 2000.
60. Kim, EE, Lee, K-S, Kim, JS, Ha, CS, Wong FC and Podoloff, DA. Primary gynecologic lymphomas evaluated by Ga-67 SPECT and CT. J Nucl Med 40(5):214P, 1999.
61. Wong FCL, Jaeckle, KA, Kim, EE, Podoloff, DA. Whole-body scintigraphic estimation of clearance of In-111 DTPA in the CSF of patients with VP shunt. Neurology 52(suppl):A198, 1999.
62. Wong, FCL, Jaeckle, KA, Kim, EE, Podoloff, DA. Study of CSF dynamics in patients with VP shunt. J Nucl Med 40(5):272-273P, 1999.
63. Wong FC, Jaeckle KA, Kim EE, Podoloff DA. Whole-body scintigraphic estimation ofclearance on In-111 DTPA in the CSF of patients with VP shunt. Neuorology 52:A198, 1999.
64. Wong FC, Jaeckle KA, Kim EE, Podoloff DA. Study of CSF dynamics in patients with VP shunt. J. Nucl. Med 40(5):272-273, 1999.
65. Wong FC, Jaeckle KA, Kim EE Macey D, McCullough S, Podoloff DA. Semi-quantitative evaluation of CSF flow by whole-body imaging in cancer patients with leptomeningeal carcinomatosis. Clinical Nuclear Medicine, 1998.
66. Wong FC, Jaeckle KA, Kim EE, Ilgan S, Podoloff DA. Whole-body ommayogram in the evaluation of CSF flow in patients with leptomeningeal carcinomatosis (LC). Europ. J. of Nucl. Med 25(8):1075, 1998.
67. Wong FC, Jaeckle KA, Kim EE, McCullough S, Macey D, Podoloff DA. Delayed clearance of In-11 DTPA from cerebral spinal fluid (CFS) correlates with signs of obstruction in patients with leptomeningeal carcinomatosis (LC). Neurology 50(4):A382, 1998.
68. Wong FC, Jaeckle KA, Kim EE, Macey D, Wendt RE, Ilgan S, Podoloff DA. CSF clearance of In-111 DTPA correlates with obstructive symptoms in patients with leptomeningeal carcinomatosis. J. Nucl. Med 39:210, 1998.
69. Yang DJ, Wong FC, Kim CG, Liu CW, Tansey LW, Oriuchi N, Lee BN, Kim EE, Podoloff DA. Synthesis and evaluation of uracil analogues in tumor-bearing rodents for PET and SPECT assessment of tumor cell proliferation. Pharm. Res 14(11):397, 1997.
70. Yang DJ, Cherif A, Wong FC, Zareneyrizi F, Choe JG, Liu CW, Kim EE, Podoloff DA. In vivo tissue distribution of radioiodinated emodin and rutin: tyrosine kinase inhibitors. Pharm Res 14(11):397, 1997.
71. Podoloff DA, Fayad L, Delpassand ES, Kim EE, Wong FC, Broussard WS, Cabanillas FF. Utility of early cycle Gallium-67 citrate imaging in intermediate grade lymphoma. Radiology 478:205, 1997.
72. Kim CG, Kim EE,Wong FC, Hong SC, Theriault R, Nicholson GL. Correlation between bone scan findings and heparinase or collagenase activities in patients with breast cancer. J. Nucl. Med 37(5):127, 1996.
73. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Podoloff DA. Comparison of F-18 FDG and C-11 MET PET in detection of residual or recurrent malignant tumors. J. Nucl. Med 37(5):261, 1996.
74. Charif H, Kim EE, Babian R, Wong FC, Podoloff DA. Significance of changing PSA levels related to serial bone scans in patients with prostate cancer. J. Nucl. Med 37(5):296, 1996.
75. Inoue T, Bassa P, Kim EE, Wong FC, Yang DJ, Podoloff DA. Detection of recurrent of residual lung cancer by PET usig F-18 FDG. Clin. Nuc. Med 20(1):91, 1995.
76. Macey DJ, Wong FC, GRant EJ, Podoloff DA. A quadruple-energy window (QEW) method for scatter subtraction with In-111. J. Nucl. Med 36:178, 1995.
77. Kim EE, Garcia JR, Wong FC, Kim CG, Broussard W, Podoloff DA. Comparison of gluorodeoxyglucose (FDG) PET and sestamibi (MIBI) SPECT in detection of residual or recurrent musculoskeletal sarcoma. J. Nucl. Med 36:234, 1995.
78. Kim EE, Garcia JR, Wong FC, Podoloff DA, Nam K, Wong WH, Tilbury RS. Evaluation of residual or recurrent muscolskeletal sarcomas using F-18 FDG PET and Tc-99m MIBI SPECT. A.J.R 162(3):279, 1994.
79. Kim EE, Garcia JR, Wong FC, Hagemeister FB, Wong WH, Haynie TP, Yang DJ, Podoloff DA. Differentiation of bone lymphoma from post-treatment changes using PET with F-18 FDG. J. Nucl. Med 35(5):35, 1994.
80. Kim EE, Garcia JR, Wong FC, Wng WH, Haynie TP, Yang DJ, Komaki R, Podoloff DA. Differentiation of thoracic tumors from post-treatment changes using PET with F-18 FDG and C-11 methionine. J. Nucl. Med 35(5):76, 1994.
81. Garcia JR, Kim EE, Wong FC, Hagemeister FB, Haynie TP, Wong WH, Yang DJ, Podoloff DA. Ga-67 citrate scan in the differentiation of bone lymphoma from post-treatment changes: comparison with FDG-pet scan. J. Nucl. Med 35(5):131, 1994.
82. Wong FC, Garcia JR, Yung A, Kim EE, Levin VA, Leeds NE, Podoloff DA. Comparison of Thallium 20 (T1) SPECT and F-18 Fluoro-deoxyglucose (FDG PET in the evaluation of MRI lesions in patients with gliomas after therapy. J. Nucl. Med 35(5):220, 1994.
83. Wong FC, Garcia JR, Kim EE, Wong WH, Podoloff DA. Normal organ uptake of F-18 fluorodeoxyglucose (FDG) and c-11 methionine (MET) during PET scans of oncologic patients. J. Nucl. Med 35(5):220, 1994.
84. Wong FC, Kim EE, Yung WKA, Levin VA, Podoloff DA. Pharmacologic perturbation as a potential tool to increase the sensitivity of FDG-PET in the evaluation of brain tumors. J. Nucl. Med 35:228, 1994.
85. Kim EE, Korkmaz M, Wong FC, Nam KJ, Podoloff DA. Utility of Tc00m RBC SPECT in the evaluation of hepatic lesions in various cancer patients. Clin. Nucl. Med 19:264, 1994.
86. Patel SR, Garcia JR, Kim EE, Wong FC, Benjamin RS, Podoloff DA. Comparative evaluation of FDG PET scans and Sestamibi SPECT scans in bone and soft tissue sarcomas. Am. Asso. Cancer Res Program 85:83, 1994.
87. Kim EE, Korkmaz M, Wong FC, Podoloff DA, Wong WH, Tilbury RS, Haynie TP, Lee J, Putnam J. Differentiation of active lung tumors from posttreatment changes using F-18 FDG PET. Clin. Nucl. Med 18(2):173, 1993.
88. Wong FC, Kim EE, Korkmaz M, Wong WH, Hicks K, Tilbury R, Yung A, Tansey W, Haynie TP. Metabolic Imaging of Brain Tumors. Clin. Nucl. Med 18(2):177, 1993.
89. Wong FC, Ho B, Lu JG, Fan SH, Myen R, Yang DJ, Kim EE. Affinity Labeling of Neuroreceptors using Gamma Rays. J. Nucl. Med 34(5):33, 1993.
90. Korkmaz M, Kim EE, Wong FC, Haynie T, Wong WH, Tibury R, Benajmin R. FDG and methionine PET in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes. J. Nucl. Med 34(5):33, 1993.
91. Kim EE, Korkmaz M, Wong FC, Haynie TP, Podoloff DA, Wong WH, Tilbury R, Yang DJ, Leeds NE, Yung A, Benjamin R. Methionine PET in the differentiation of residual or recurrent tumor from posttreatment changes. J. Nucl. Med 34(5):42, 1993.
92. Kim EE, Korkmaz M, Wong FC, Podoloff DA, Haynie TP, Wong WH, Tilbury R, Lee J, Putnam J. PET differentiation of residual or recurrent chest tumors from posttreatment changes. J. Nucl. Med 34(5):55, 1993.
93. Wong FC, Kim EE, Korkmaz M, Wong WH, Tilbury R, Tansey W, Kicks K, Haynie TP. The effects of intraveneous persantine on regional cerebral blood flow in normal subjects. J. Nucl. Med 34(5):68, 1993.
94. Korkmaz M, Kim EE, Wong FC, Isiklar I, Podoloff DA, Haynie TP, Yung A. Utility of radionuclide ommayograms in patients with leptomeningeal carcinomatosis. J. Nucl. Med 34(5):204, 1993.
95. Wong FC, Kim EE, Korkmaz M, Wong WH, Haynie TP, Yung A, Sawaya R. Semi-quantitative assessment of recurrent brain tumors with PET using C11-methionine and F-18 FDG. J. Nucl. Med 34(5):206, 1993.
96. Kim EE, Wong FC, Korkmaz M, Komaki R, Wong WH, Tilbury RS. Differential Diagnosis of recurrent lung cancers from posttreatment changes by using F-18 FDG PET. Radiology 147:189, 1993.
97. Kim EE, Moon TY, Wong FC, Wong WH, Delpassand E, Podoloff DA, et al.. Role of FDG PET in the evaluation of therapeutic responses in bone lymphoma. Radiology 200:89, 1993.
98. Wong FC, Kim EE, Wong WH, et al.. Suppression of FDG Uptake in Brain Tumors During Hyperglycemia. Radiology 201:189, 1993.
99. Haynie TP, Wong FC, Kim EE, Wong WH, Tilbury R, Korkmax M, Podoloff DA. Somparison of C-11 methionine and F-18 FDG for tumor imaging with positron emission tomography (PET). Eur. J. of Nucl. Med 20:829, 1993.
100. Wong DF, Shaya E, Wilson PD, Wong FC, et al.. Simultanious in vivo measurement of human dopamine and serotonin Bmax using high and low specific activity [C-11]NMSP and a unified estimation procedure. J. Nucl. Med 32:1008, 1991.
101. Wong FC, Boja J, Wong DF, et al.. X-ray affinity labelling of dopamine transporter with photoaffinity ligands. J. Nucl. Med 32:1939, 1991.
102. Wong FC, Swartz BE, Mandelkern M, Escueta AV, Mintz L, Rochan J, Quinones N, Gee M, Blahd WH. Visual field defects and striatal cortex hypometabolism in postlobectomy epileptic patients. J. Nucl. Med 31:881, 1990.
103. Wong FC, Swartz BE, Mintz L, Mandelkern M, Rophan J, Quinones N, Blahd WH. Pre-and postoperative hypometabolism of the striate cortex in temporal lobe epilepsy-diaschisis or deafferentation?. Epilepsia 31(5):671-672, 1990.
104. Halfman CJ, Dowe RJ, Wong FC, Schneider AS. Elimination of specimen binding with dodecyl sulfate in a fluorescent labeled immunoassay for total thyroxine. Clin Chem 31(6):954, 1985.
105. Wong FC, Halfman CJ, Schneider AS. Optimization of a T4 FIA with considerations of different affinities of labeled and unlabeled analyte. Clin. Chem 30(6):1035-1036, 1984.
106. Halfman CJ, Wong FC, Schneider AS. Polarized emission components as response variables in fluorescence immunoassays. Clin. Chem 29(6):1179, 1983.
107. Halfman CJ, Wong FCL. Solvent quenching fluorescence immunoassay. Clinical Chemistry 28(7):1657, 1982.
108. Wong FCL, Halfman CJ, Schneider AS. An improved response variable for fluorescence plarization immunoassays. Clinical Chemistry 28(7):1658, 1982.

Book Chapters

1. Wong FCL, Hicks ME. Multimodality Image-Guided Treatment. In: Cancer Theranostics. Elsiever, 2014.
2. Wong FC. Locoregional Radionuclide Therapy of Primary and Metastatic Cancers. In: Therapeutic Nuclear Medicine. 1. Springer Berlin Heidelberg: New York, Dordrecht, London, 703-16, 2014.
3. Wong FCL, Duan XY, Kim EE. Brain Tumors. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 187-98, 2013.
4. Wong FCL, Duan XY, Kim EE. Head and Neck Tumors. In: Clinical PET and PET-CT: Principles and Applications. 2. Springer: New York, 199-214, 2013.
5. Kim EE, Wong FCL. Technical Principles, Radiation Safety, and Image Interpretation. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 89-98, 2013.
6. Kim EE, Wong FCL. Lung and Pleural Cancers. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 215-26, 2013.
7. Kim EE, Wong FCL. Lymphoma. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 301-8, 2013.
8. Kim EE, Wong FCL. Melanoma, Myeloma, and Sarcoma. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 309-16, 2013.
9. Kim EE, Wong FCL. Cost Analysis and Effectiveness of PET and PET/CT. In: Clinical PET and PET/CT: Principles and Applications. 2. Springer: New York, 85-8, 2013.
10. Kim EE, Wong FCL. Pulmonary Nuclear Medicine. In: Handbook of Nuclear Medicine and Molecular Imaging. 1. World Scientific: New Jersey, 207-20, 2012.
11. Kim EE, Wong FCL. Lymphoscintigraphy and Venography. In: Handbook of Nuclear Medicine and Molecular Imaging. 1. World Scientific: New Jersey, 327-32, 2012.
12. Wong FCL, Kim EE. Therapeutical Applications of Radionuclides. In: Handbook of Nuclear Medicine and Molecular Imaging. 1. World Scientific: New Jersey, 401-34, 2012.
13. Kim EE, Wong FC. Scintigraphic Imaging of Cerebral Spinal Fluid Flow, Blockage, and Leakage. In: Handbook of Nuclear Medicine and Molecular Imaging. 1. World Scientific: New Jersey, 153-62, 2012.
14. Murphy WA, Gladish GW, Gupta S, Kumar AJ, Matamoros A, Wong FC. Imaging. In: Medical Care of Cancer Patients. 1. BC Decker, Inc: Shelton, Connecticut, 111-127, 2009.
15. Kim, EE, Wong FC. Radiation Dosimetry and Safety in Lymphoscintigraphy. In: Mastery of Lymphatic Mapping. 1. Springer-Verlag: New York, 2007.
16. Pettaway C, Wong FC. Lymphatic Mapping in Penile Cancer: Feasibility, Techniques, and Early Results. In: Mastery of Lymphatic Mapping. 1. Springer: New York, 2007.
17. Kim EE, Wong FC. Melanoma, Myeloma and Sarcoma. In: Clinical PET: Basic Principles and Clinical Applications. 1. Springer-Verlag: New York, 357-371, 2004.
18. Kim EE, Wong FC. Lymphoma. In: Clinical PET: Basic Principles and Clinical Applications. 1. Springer-Verlag: New York, 372-386, 2004.
19. Kim EE, Wong FC. Technical Considerations. In: Clinical PET: Principles and Clinical Applications. 1. Springer-Verlag: New York, 117-126, 2004.
20. Wong FCL, Kim EE. Brain tumors. In: Clinical PET: Basic Principles and Clinical Applications. 1. Springer-Verlag: New York, 228-246, 2004.
21. Wong FCL, Kim EE. Head and Neck Tumors. In: Clinical PET: Basic Principles and Clinical Applications. 1. Springer-Verlag: New York, 247-261, 2004.
22. Fuller, GN, Ribalta T, Zhang W, Aldape KD, Singh SK, Jackson EF, Wong FC. XII. Neuro-Oncology. Diagnostic Techniques. In: Atlas of Cancer. 2. Lippincott Williams & Wilkins: Philadelphia, 542-560, 2003.
23. Kim EE, Wong FC. Thoracic Cancer. In: Clinical PET: Basic Principles and Clinical Applications. 1. Springer-Verlag: New York, 262-282, 2003.
24. Wong FC, Kim EE. Nuclear Medicine in Neuro-Oncology. In: Cancer in the Nervous System. 2. Oxford Univ. Press: New York, 60-72, 2002.
25. Wong FC, Podoloff DA. Evaluation of Ventricular Shunts and Pumps Via Radionuclide Technique. In: Nuclear Oncology: Diagnosis and Therapy. 1. Lippincott, Williams & Wilkins: Philadelphia, 183-186, 2001.
26. Kim EE, Wong FC. Targeted SPECT in Oncology. In: Targeted Molecular Imaging in Oncology. 1. Springer: New York, 121-133, 2000.
27. Kim EE, Wong FC. Targeted PET in Oncology. In: Targeted Molecular Imaging in Oncology. 1. Springer: New York, 134-154, 2000.
28. Wong FC, Kim EE. Peptide Receptor Imaging. In: Targeted molecular Imaging in Oncology. 1. Springer: New York, 102-110, 2000.
29. Wong FC, Kim EE. Brain Tumor Imaging. In: Molecular Imaging in Oncology (MRI, MRS, and PET). 1. Springer-Verlag: Heidelberg, 211-230, 1999.
30. Wong FCL, Kim EE. Head and Neck Tumor Imaging. In: Molecular Imaging in Oncology (MRI, MRS, and PET. 1. Springer-Verlag: Heidelberg, 231-242, 1999.
31. Wong FC, Kim EE. Receptor Imaging in Oncology. In: Molecular Imaging in Oncology (MRI, MRS, and PET. 1. Springer-Verlag: Heidelberg, 101-106, 1999.
32. Wong FC, Kim E E. Nuclear medicine studies. In: Cancer in the Nervous System. 1. Churchill Livingstone: New York, 50-55, 1996.
33. Wong FC. Optimization of response variables and reactant concentration in fluorescent labeled-ligand binding assays. In: Ph.D. Dissertation, University of Health Sciences. The Chicago Medical School, 1984.
34. Wong FC. Drug induced audiogenic seizure and its suppression. In: M.S. Thesis, University of Arizona,, 1980.